Personalized medicine for chronic, complex diseases: Chronic obstructive pulmonary disease as an example

Personalized Medicine

Volumn 11, Issue 7, 2014, Pages 669-679

  Radder, Josiah E ^a   Shapiro, Steven D ^a,b   Berndt, Annerose ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

chronic obstructive pulmonary disease; clinical decision support system; electronic health record; enterprise data warehouse; next generation sequencing; phenotyping; pulmonary

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; PERSONALIZED MEDICINE; REVIEW;

EID: 84909944126     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.14.51     Document Type: Review

References (93)

1. Lander ES, Linton LM, Birren B Initial sequencing and analysis of the human genome. Nature 409 (6822), 860-921 (2001).
2. Hoffman EP. The Evolving Genome Project: current and future impact. Am. J. Hum. Genet. 54 (1), 129-136 (1994).
3. Green ED, Waterston RH. The human genome project. Prospects and implications for clinical medicine. JAMA 266 (14), 1966-1975 (1991).
4. Langreth R, Waldholz M. New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist 4 (5), 426-427 (1999).
5. Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J. 6 (1), 16-21 (2006).
6. Silverman EK, Loscalzo J. Developing new drug treatments in the era of network medicine. Clin. Pharmacol. Ther. 93 (1), 26-28 (2013).
7. Hall IP. Stratified medicine: drugs meet genetics. Eur. Respir. Rev. 22 (127), 53-57 (2013).
8. Robinson PN. Deep phenotyping for precision medicine. Hum. Mutat. 33 (5), 777-780 (2012).
9. Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J. Int. Med. 271 (2), 111-121 (2012).
10. Hall JM, Lee MK, Newman B Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250 (4988), 1684-1689 (1990).
11. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (5645), 643-646 (2003).
12. Cuzick J, Sestak I, Bonanni B Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381 (9880), 1827-1834 (2013).
13. Jelovac D, Emens LA. HER2-directed therapy for metastatic breast cancer. Oncology 27 (3), 166-175 (2013).
14. Balachandran VP, Dematteo RP. Targeted therapy for cancer: the gastrointestinal stromal tumor model. Surg. Oncol. Clin. North Am. 22 (4), 805-821 (2013).
15. Chapman PB, Hauschild A, Robert C Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364 (26), 2507-2516 (2011).
16. Paez JG, Janne PA, Lee JC EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (5676), 1497-1500 (2004).
17. Ritchie MD. The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era. Hum. Genet. 131 (10), 1615-1626 (2012).
18. Becquemont L. HLA: a pharmacogenomics success story. Pharmacogenomics 11 (3), 277-281 (2010).
19. WHO. The global burden of disease: 2004 update (2008). www.who.int/healthinfo/global-burden-disease/GBD-report-2004update-full.pdf?ua1.
20. Agusti A, MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax 68 (7), 687-690 (2013).
21. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. (2013). www.goldcopd.org/uploads/users/files/GOLD-Report-2013-Feb20.pdf.
22. Chapman KR, Mannino DM, Soriano JB Epidemiology and costs of chronic obstructive pulmonary disease. Eur. Respir. J. 27 (1), 188-207 (2006).
23. Han MK, Agusti A, Calverley PM Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 182 (5), 598-604 (2010).
24. Bon J, Liao S, Tseng G, Sciurba FC. Considerations and pitfalls in phenotyping and reclassification of chronic obstructive pulmonary disease. Transl. Res. 162 (4), 252-257 (2013).
25. Vestbo J, Agusti A, Wouters EF Should we view chronic obstructive pulmonary disease differently after ECLIPSE?. A clinical perspective from the study team. Am. J. Respir. Crit. Care Med. 189 (9), 1022-1030 (2014).
26. Regan EA, Hokanson JE, Murphy JR Genetic epidemiology of COPD (COPDGene) study design. COPD 7 (1), 32-43 (2010).
27. Jamoom E, Beatty P, Bercovitz A Physician adoption of electronic health record systems: United States, 2011. Number 98 (2012). www.cdc.gov/nchs/data/databriefs/db98.htm.
28. Blumenthal D, Tavenner M. The meaningful use regulation for electronic health records. N. Engl. J. Med. 363 (6), 501-504 (2010).
29. Hsu J, Pacheco JA, Stevens WW, Smith ME, Avila PC. Accuracy of phenotyping chronic rhinosinusitis in the electronic health record. Am. J. Rhinol. Allergy 28 (2), 140-144 (2014).
30. Tian TY, Zlateva I, Anderson DR. Using electronic health records data to identify patients with chronic pain in a primary care setting. JAMIA 20 (e2), e275-e280 (2013).
31. Macaulay D, Sun SX, Sorg RA Development and validation of a claims-based prediction model for COPD severity. Respir. Med. 107 (10), 1568-1577 (2013).
32. Jones RC, Price D, Ryan D Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir. Med. 2 (4), 267-276 (2014).
33. Castaldi PJ, Dy J, Ross J Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. Thorax 69 (5), 415-422 (2014).
34. Burgel PR, Paillasseur JL, Caillaud D Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur. Respir. J. 36 (3), 531-539 (2010).
35. Larson RK, Barman ML, Kueppers F, Fudenberg HH. Genetic and environmental determinants of chronic obstructive pulmonary disease. Ann. Intern. Med. 72 (5), 627-632 (1970).
36. Redline S, Tishler PV, Lewitter FI, Tager IB, Munoz A, Speizer FE. Assessment of genetic and nongenetic influences on pulmonary function. A twin study. Am. Rev. Respir. Dis. 135 (1), 217-222 (1987).
37. Chen Y, Horne SL, Rennie DC, Dosman JA. Segregation analysis of two lung function indices in a random sample of young families: the Humboldt Family Study. Genet. Epidemiol. 13 (1), 35-47 (1996).
38. Givelber RJ, Couropmitree NN, Gottlieb DJ Segregation analysis of pulmonary function among families in the Framingham Study. Am. J. Respir. Crit. Care Med. 157 (5 Pt 1), 1445-1451 (1998).
39. Kueppers F, Briscoe WA, Bearn AG. Hereditary deficiency of serum alpha L-antitrypsin. Science 146 (3652), 1678-1679 (1964).
40. Laurell CB. Electrophoretic microheterogeneity of serum alpha-1 antitrypsin. Scand. J. Clin. Lab. Invest. 17, 271-274 (1965).
41. Jeppsson JO, Laurell CB, Fagerhol M. Properties of isolated human alpha1-antitrypsins of Pi types M, S and Z. Eur. J. Biochem. 83 (1), 143-153 (1978).
42. Molloy K, Hersh CP, Morris VB Clarification of the risk of chronic obstructive pulmonary disease in alpha1-antitrypsin deficiency PiMZ heterozygotes. Am. J. Respir. Crit. Care Med. 189 (4), 419-427 (2014).
43. Rahaghi FF, Sandhaus RA, Brantly ML The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. COPD 9 (4), 352-358 (2012).
44. Cho MH, Castaldi PJ, Wan ES A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum. Mol. Genet. 21 (4), 947-957 (2012).
45. Kong X, Cho MH, Anderson W Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. Am. J. Respir. Crit. Care Med. 183 (1), 43-49 (2011).
46. Obeidat M, Wain LV, Shrine N A comprehensive evaluation of potential lung function associated genes in the SpiroMeta general population sample. PLoS ONE 6 (5), e19382 (2011).
47. Pillai SG, Ge D, Zhu G A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 5 (3), e1000421 (2009).
48. Soler Artigas M, Loth DW, Wain LV Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat. Genet. 43 (11), 1082-1090 (2011).
49. Hersh CP, Silverman EK, Gascon J SOX5 is a candidate gene for chronic obstructive pulmonary disease susceptibility and is necessary for lung development. Am. J. Respir. Crit. Care Med. 183 (11), 1482-1489 (2011).
50. Repapi E, Sayers I, Wain LV Genome-wide association study identifies five loci associated with lung function. Nat. Genet. 42 (1), 36-44 (2010).
51. Manichaikul A, Hoffman EA, Smolonska J Genome-wide study of percent emphysema on CT in the general population: the MESA Lung/SHARe study. Am. J. Respir. Crit. Care Med. 189 (4), 408-18 (2014).
52. Berndt A, Leme AS, Shapiro SD. Emerging genetics of COPD. EMBO Mol. Med. 4 (11), 1144-1155 (2012).
53. Wain LV, Soler Artigas M, Tobin MD. What can genetics tell us about the cause of fixed airflow obstruction? Clin. Exp. Allergy 42 (8), 1176-1182 (2012).
54. Hardin MS, Silverman EK. Chronic obstructive pulmonary disease genetics: a review of the past and a look into the future. Chronic Obstr. Pulm. Dis. 1 (1), 33-46 (2014).
55. Zhou X, Baron RM, Hardin M Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. Hum. Mol. Genet. 21 (6), 1325-1335 (2012).
56. Zhou JJ, Cho MH, Castaldi PJ, Hersh CP, Silverman EK, Laird NM. Heritability of chronic obstructive pulmonary disease and related phenotypes in smokers. Am. J. Respir. Crit. Care Med. 188 (8), 941-947 (2013).
57. Gibson G. Rare and common variants: twenty arguments. Nat. Rev. Genet. 13 (2), 135-145 (2011).
58. Visscher PM, Brown MA, Mccarthy MI, Yang J. Five years of GWAS discovery. Am. J. Hum. Genet. 90 (1), 7-24 (2012).
59. Wjst M, Sargurupremraj M, Arnold M. Genome-wide association studies in asthma: what they really told us about pathogenesis. Curr. Opin. Allergy Clin. Immunol. 13 (1), 112-118 (2013).
60. Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on genomics. Cell 155 (1), 27-38 (2013).
61. Steinthorsdottir V, Thorleifsson G, Sulem P. Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of Type 2 diabetes. Nat. Genet. 46 (3), 294-298 (2014).
62. Service SK, Teslovich TM, Fuchsberger C Re-sequencing expands our understanding of the phenotypic impact of variants at GWAS loci. PLoS Genet. 10 (1), e1004147 (2014).
63. Wetterstrand K. DNA sequencing costs: data from the NHGRI Genome Sequencing Program (GSP) (2014). www.genome.gov/sequencingcosts.
64. Sboner A, Mu XJ, Greenbaum D, Auerbach RK, Gerstein MB. The real cost of sequencing: higher than you think! Genome Biol. 12 (8), 125 (2011).
65. Manichaikul A, Hoffman EA, Smolonska J Genome-wide study of percent emphysema on computed tomography in the general population. the Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study. Am. J. Respir. Crit. Care Med. 189 (4), 408-418 (2014).
66. Manchia M, Cullis J, Turecki G, Rouleau GA, Uher R, Alda M. The impact of phenotypic and genetic heterogeneity on results of genome wide association studies of complex diseases. PLoS ONE 8 (10), e76295 (2013).
67. Danciu I, Cowan JD, Basford M Secondary use of clinical data: the Vanderbilt approach. J. Biomed. Inform. doi:10.1016/j.jbi.2014.02.003 (2014) (Epub ahead of print).
68. Costa FF. Big data in biomedicine. Drug Discov. Today 19 (4), 433-440 (2014).
69. Dixon BE, Vreeman DJ, Grannis SJ. The long road to semantic interoperability in support of public health: experiences from two states. J. Biomed. Inform. 49, 3-8 (2014).
70. Campion TR Jr, Edwards AM, Johnson SB, Kaushal R. Health information exchange system usage patterns in three communities: practice sites, users, patients, and data. Int. J. Med. Inform. 82 (9), 810-820 (2013).
71. Botsis T, Hartvigsen G, Chen F, Weng C. Secondary use of EHR. Data quality issues and informatics opportunities. AMIA Jt Summits Transl. Sci. Proc. 1-5 (2010).
72. Adler-Milstein J, Jha AK. Healthcare's big data challenge. Am. J. Manag. Care 19 (7), 537-538 (2013).
73. Coorevits P, Sundgren M, Klein GO Electronic health records: new opportunities for clinical research. J. Int. Med. 274 (6), 547-560 (2013).
74. Electronic Health Records for Clinical Research (2014). www.ehr4cr.eu.
75. Doods J, Botteri F, Dugas M, Fritz F. A European inventory of common electronic health record data elements for clinical trial feasibility. Trials 15 (1), 18 (2014).
76. Starren J, Williams MS, Bottinger EP. Crossing the omic chasm: a time for omic ancillary systems. JAMA 309 (12), 1237-1238 (2013).
77. Kho AN, Pacheco JA, Peissig PL Electronic medical records for genetic research: results of the eMERGE Consortium. Sci. Transl. Med. 3 (79), 79-71 (2011).
78. The eMerge Network. http://emerge.mc.vanderbilt.edu.
79. Zuvich RL, Armstrong LL, Bielinski SJ Pitfalls of merging GWAS data: lessons learned in the eMERGE network and quality control procedures to maintain high data quality. Genet. Epidemiol. 35 (8), 887-898 (2011).
80. Denny JC, Ritchie MD, Basford MA PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics 26 (9), 1205-1210 (2010).
81. Ritchie MD, Denny JC, Crawford DC Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am. J. Hum. Genet. 86 (4), 560-572 (2010).
82. Namjou B, Keddache M, Marsolo K EMR-linked GWAS study: investigation of variation landscape of loci for body mass index in children. Front. Genet. 4, 268 (2013).
83. Calverley PM. The GOLD classification has advanced understanding of COPD. Am. J. Respir. Crit. Care Med. 170 (3), 211-212 ; discussion 214 (2004).
84. Belletti D, Liu J, Zacker C, Wogen J. Results of the CAPPS. COPD-assessment of practice in primary care study. Curr. Med. Res. Opin. 29 (8), 957-966 (2013).
85. Bertella E, Zadra A, Vitacca M. COPD management in primary care: is an educational plan for GPs useful? Multidiscip. Respir. Med. 8 (1), 24 (2013).
86. Steurer-Stey C, Dallalana K, Jungi M, Rosemann T. Management of chronic obstructive pulmonary disease in Swiss primary care: room for improvement. Qual. Prim. Care 20 (5), 365-373 (2012).
87. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ 330 (7494), 765 (2005).
88. Cooley ME, Blonquist TM, Catalano PJ Feasibility of Using Algorithm-Based Clinical Decision Support for Symptom Assessment and Management in Lung Cancer. J. Pain Symptom Manage. doi:10.1016/j.jpainsymman.2014.05.003 (2014) (Epub ahead of print).
89. Matui P, Wyatt JC, Pinnock H, Sheikh A, Mclean S. Computer decision support systems for asthma: a systematic review. NPJ Prim. Care Respir. Med. 24, 14005 (2014).
90. Karlsson D, Forsum U. Medical decision-support systems and the concept of context. Med. Inform. Internet Med. 29 (2), 109-118 (2004).
91. Eberhardt J, Bilchik A, Stojadinovic A. Clinical decision support systems: potential with pitfalls. J. Surg. Oncol. 105 (5), 502-510 (2012).
92. Turner S, Armstrong LL, Bradford Y Quality control procedures for genome-wide association studies. Curr. Protoc. Hum. Genet. Chapter 1, Unit 19 (2011).
93. Mosley JD, Van Driest SL, Larkin EK Mechanistic phenotypes: an aggregative phenotyping strategy to identify disease mechanisms using GWAS data. PLoS ONE 8 (12), e81503 (2013).